Vitamin D status and HIV-related complications in children and young adults

儿童和年轻人的维生素 D 状况和 HIV 相关并发症

基本信息

  • 批准号:
    8601740
  • 负责人:
  • 金额:
    $ 12.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-01-02 至 2016-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Vitamin D is critical in many physiologic and pathophysiologic processes including inflammatory status, immune function, and cardiovascular health. Vitamin D deficiency is widespread among HIV-infected adults and children. This is particularly alarming since there is a higher risk than the general population for complications like osteoporosis, non-AIDS-defining malignancies, and cardiovascular disease (CVD) - all diseases associated with vitamin D deficiency. It is not known how much vitamin D deficiency heightens the risk of complications like CVD, affects immune function and disease progression, or interferes with optimal treatment in the HIV population. The impact of vitamin D deficiency in the HIV population may be compounded even further since the etiology of HIV-related complications like CVD is thought to be related in part to inflammation and detrimental endothelial effects associated with chronic HIV infection-similar proposed mechanisms as vitamin D deficiency. Data suggest that optimal vitamin D status may be protective against these HIV-related complications, and optimizing vitamin D status with oral supplementation in HIV-infected individuals may improve the risk of HIV-related complications by decreasing inflammation and/or improving endothelial dysfunction, and may improve immune function even in individuals on antiretroviral therapy. Developing suitable repletion strategies is crucial to maximizing health status, particularly in HIV-infected children and young adults, where an opportunity exists for disease prevention. However, the best method of vitamin D repletion is not known, and data suggest that some antiretroviral medications interfere with vitamin D metabolism. Thus, we hypothesize that (1) optimizing vitamin D status to the current Institute of Medicine's (IOM) suggested 25-hydroxyvitamin D (25(OH)D) concentration of e20 ng/mL improves CVD risk, inflammation, and CD4 cell counts in HIV-infected individuals, (2) increasing 25(OH)D concentrations to >30 ng/mL improves CVD risk and inflammation to a greater degree than increasing eto 20 ng/mL (the concentration some experts consider optimal for cardiovascular health), and (3) a "high dose" of oral vitamin D is necessary to achieve 25(OH)D concentrations >30 ng/mL. These hypotheses will be addressed by determining the longitudinal relationships between serum 25(OH)D concentrations, carotid intima-media thickness, pulse wave velocity, pro-inflammatory biomarkers, and CD4 cell counts in HIV-infected children and young adults in a double-blinded, randomized-controlled trial of three different vitamin D dosing regimens given over 24 months in HIV-infected children and young adults (ages 10-25 years) with vitamin D deficiency (25(OH)D <20 ng/mL). We will also evaluate the 25(OH)D concentrations from each arm after 6, 12, and 24 months of supplementation, in order to determine a dose-response relationship. These findings could have a sizable impact on health in this population, since vitamin D therapy is inexpensive and associated with few adverse side effects. The PI is an exceptional candidate who is a pediatric infectious diseases specialist with a proven research focus in the metabolic and cardiovascular complications of HIV. She is mentored by a committed, multidisciplinary team of senior investigators with extensive experience in both mentoring and in the research methodologies relevant to this proposal. Future training in all aspects of clinical research, cardiovascular disease risk assessment, and clinical nutrition is planned to facilitate the PI's development into a successful independent physician scientist.
描述(由申请人提供):维生素D在许多生理和病理生理过程中至关重要,包括炎症状态、免疫功能和心血管健康。维生素D缺乏症在感染艾滋病毒的成人和儿童中普遍存在。这尤其令人担忧,因为与普通人群相比,他们患骨质疏松症、非艾滋病恶性肿瘤和心血管疾病(CVD)等并发症的风险更高——所有这些疾病都与维生素D缺乏有关。目前尚不清楚维生素D缺乏会在多大程度上增加心血管疾病等并发症的风险,影响免疫功能和疾病进展,或干扰艾滋病毒人群的最佳治疗。维生素D缺乏对艾滋病毒人群的影响可能会进一步加剧,因为艾滋病毒相关并发症(如心血管疾病)的病因被认为部分与慢性艾滋病毒感染相关的炎症和有害的内皮效应有关——类似于维生素D缺乏的机制。数据表明,最佳的维生素D状态可能对这些hiv相关并发症具有保护作用,并且在hiv感染者中通过口服补充维生素D来优化维生素D状态可能通过减少炎症和/或改善内皮功能障碍来改善hiv相关并发症的风险,并且甚至可以改善抗逆转录病毒治疗个体的免疫功能。制定适当的补充战略对于最大限度地提高健康状况,特别是感染艾滋病毒的儿童和青年的健康状况至关重要,因为那里存在预防疾病的机会。然而,补充维生素D的最佳方法尚不清楚,数据表明一些抗逆转录病毒药物会干扰维生素D的代谢。因此,我们假设(1)优化维生素D状态,达到目前医学研究所(IOM)建议的25-羟基维生素D (25(OH)D)浓度为e20 ng/mL可改善艾滋病毒感染者的心血管疾病风险、炎症和CD4细胞计数;(2)将25(OH)D浓度提高到bb30 ng/mL比将25(OH)D浓度提高到e20 ng/mL(一些专家认为对心血管健康最理想的浓度)更大程度地改善心血管疾病风险和炎症。(3)需要“高剂量”口服维生素D才能使25(OH)D浓度达到50 ~ 30 ng/mL。这些假设将通过确定血清25(OH)D浓度、颈动脉内膜-中膜厚度、脉搏波速度、促炎生物标志物和艾滋病毒感染儿童和年轻人CD4细胞计数之间的纵向关系来解决。在一项双盲、随机对照试验中,三种不同的维生素D给药方案在24个月内给予艾滋病毒感染儿童和年轻人(10-25岁)维生素D缺乏(25(OH)D <20 ng/mL)。我们还将评估每组在补充6、12和24个月后的25(OH)D浓度,以确定剂量-反应关系。这些发现可能对这一人群的健康产生相当大的影响,因为维生素D治疗价格低廉,而且几乎没有不良副作用。PI是一名特殊的候选人,他是一名儿科传染病专家,在艾滋病毒的代谢和心血管并发症方面有着成熟的研究重点。她由一个忠诚的、多学科的高级研究人员团队指导,他们在指导和与本提案相关的研究方法方面都有丰富的经验。计划在临床研究、心血管疾病风险评估和临床营养等各个方面进行未来培训,以促进PI发展成为一名成功的独立内科科学家。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Allison Ross Eckard其他文献

Allison Ross Eckard的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Allison Ross Eckard', 18)}}的其他基金

Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy
GLP-1受体激动剂对HIV相关脂肪肥大心脏代谢改变的影响
  • 批准号:
    9912153
  • 财政年份:
    2019
  • 资助金额:
    $ 12.61万
  • 项目类别:
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy
GLP-1受体激动剂对HIV相关脂肪肥大心脏代谢改变的影响
  • 批准号:
    10598535
  • 财政年份:
    2019
  • 资助金额:
    $ 12.61万
  • 项目类别:
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy
GLP-1受体激动剂对HIV相关脂肪肥大心脏代谢改变的影响
  • 批准号:
    10380057
  • 财政年份:
    2019
  • 资助金额:
    $ 12.61万
  • 项目类别:
Vitamin D status and HIV-related complications in children and young adults
儿童和年轻人的维生素 D 状况和 HIV 相关并发症
  • 批准号:
    8263565
  • 财政年份:
    2012
  • 资助金额:
    $ 12.61万
  • 项目类别:
Vitamin D status and HIV-related complications in children and young adults
儿童和年轻人的维生素 D 状况和 HIV 相关并发症
  • 批准号:
    8404036
  • 财政年份:
    2012
  • 资助金额:
    $ 12.61万
  • 项目类别:
Vitamin D status and HIV-related complications in children and young adults
儿童和年轻人的维生素 D 状况和 HIV 相关并发症
  • 批准号:
    8774918
  • 财政年份:
    2012
  • 资助金额:
    $ 12.61万
  • 项目类别:

相似海外基金

Plasma 25-Hydroxyvitamin D Concentration and Incident Risk of Dementia: a Case-cohort Study
血浆 25-羟基维生素 D 浓度和痴呆症事件风险:病例队列研究
  • 批准号:
    23K19881
  • 财政年份:
    2023
  • 资助金额:
    $ 12.61万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Association between serum 25-hydroxyvitamin D and endothelium dysfunction in Japanese population
日本人群血清 25-羟基维生素 D 与内皮功能障碍之间的关联
  • 批准号:
    19K21451
  • 财政年份:
    2018
  • 资助金额:
    $ 12.61万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
A prospective study about association between 25-hydroxyvitamin D and cognitive decline and development of lifestyle-related diseases.
一项关于 25-羟基维生素 D 与认知能力下降和生活方式相关疾病发展之间关系的前瞻性研究。
  • 批准号:
    17K09121
  • 财政年份:
    2017
  • 资助金额:
    $ 12.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Direct effects of 25-hydroxyvitamin D on renal fibrosis
25-羟基维生素 D 对肾纤维化的直接影响
  • 批准号:
    26461227
  • 财政年份:
    2014
  • 资助金额:
    $ 12.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Pooled Analysis of 25-hydroxyvitamin D and Colorectal Cancer Survival
25-羟基维生素 D 与结直肠癌生存的汇总分析
  • 批准号:
    8773987
  • 财政年份:
    2014
  • 资助金额:
    $ 12.61万
  • 项目类别:
C-3 alpha epimer of 25-hydroxyvitamin D origin and effects on growing bone
25-羟基维生素 D 来源的 C-3 α 差向异构体及其对骨骼生长的影响
  • 批准号:
    447751-2013
  • 财政年份:
    2013
  • 资助金额:
    $ 12.61万
  • 项目类别:
    University Undergraduate Student Research Awards
Health service utilization, vitamin D supplementation and 25-hydroxyvitamin D levels in young children
幼儿保健服务利用、维生素 D 补充和 25-羟基维生素 D 水平
  • 批准号:
    307836
  • 财政年份:
    2013
  • 资助金额:
    $ 12.61万
  • 项目类别:
    Studentship Programs
C-3 alpha epimer of 25-hydroxyvitamin D origin and effects on growing bone
25-羟基维生素 D 来源的 C-3 α 差向异构体及其对骨骼生长的影响
  • 批准号:
    447773-2013
  • 财政年份:
    2013
  • 资助金额:
    $ 12.61万
  • 项目类别:
    University Undergraduate Student Research Awards
Amelioration of Vesicant-Induced Skin Injury by High Dose 25-Hydroxyvitamin D
高剂量 25-羟基维生素 D 改善出疱剂引起的皮肤损伤
  • 批准号:
    8722316
  • 财政年份:
    2012
  • 资助金额:
    $ 12.61万
  • 项目类别:
Amelioration of Vesicant-Induced Skin Injury by High Dose 25-Hydroxyvitamin D
高剂量 25-羟基维生素 D 改善出疱剂引起的皮肤损伤
  • 批准号:
    8333049
  • 财政年份:
    2012
  • 资助金额:
    $ 12.61万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了